The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Open accessAbstract
A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers. After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug. The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK). Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6 out of 10) of the cases. KRAS mutant alleles were detectable in the blood of cetuximab-treated patients as early as 10 months before radiographic documentation of disease progression. In summary, the results identify KRAS mutations as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who initially respond to anti-EGFR develop acquired resistance within 12 to 18 months due to secondary mutations in KRAS genes, EGFR exodomain alteration, and clonal selection [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We and others previously reported that KRAS acquired mutations are responsible for secondary resistance to anti-EGFR therapies in CRC(22, 23).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Patients who fail to respond to therapy initially exhibit intrinsic resistance, whereas those who relapse after initial response are associated with acquired resistance [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
In the citing paper
“Emergence of KRAS amplification and acquisition of secondary KRAS mutations (G12C, G12D, G13D and Q61H) was detected as one mechanism of acquired resistance in metastatic CRC patients, who relapsed on cetuximab or panitumumab treatment (78, 79).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [78]
In the citing paper
“KRAS point mutations and gene copy number gains are responsible not only for primary but also for acquired resistance in 38–60 % of patients who relapse on cetuximab or panitumumab [37-39].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“KRAS alterations could be identified noninvasively 5–10 months before radiographic disease progression by analyzing cell-free circulating tumor DNA (ctDNA) [37, 38].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“however, the proof of principle that such an approach could complement tumor biopsy and provide an early warning of acquired resistance has been established [38, 41, 136].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“To address these challenges, Mirati Therapeutics conducted high-resolution crystal structure analyses of compounds bound to mutant KRAS proteins, optimizing these compounds to develop MRTX1133, a non-covalent, selective inhibitor for KRAS G12D [60].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [60]
In the citing paper
“For instance, BRAF (V600E) and MAP2K1/MEK1 (K57T, K57N, I99_K104 deletion, and E102_I103 deletion) can also cause acquired drug resistance [94, 108–111].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [110]
In the citing paper
“By performing repeat biopsies and evaluating circulating tumor DNA, investigators observed the emergence of KRAS mutations as a resistance mechanism (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
In the citing paper
“non-invasive measures such as molecular interrogation of circulating tumor cells or plasma DNA may help capture the heterogeneity of resistance in patients, as was done to identify the development of KRAS mutations in colorectal cancers that acquire resistance to cetuximab (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Self-citationMolecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Self-citationActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Cited by
Sorted by citations
Items 301–400 of 1,014
Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22789 · Cited by 97
KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation
Shukla, S., Allam, U. S., Ahsan, A., Chen, G., Krishnamurthy, P. M., Marsh, K., Rumschlag, M., Shankar, S., Whitehead, C., Schipper, M., et al. (2014) · Neoplasia · doi:10.1593/neo.14184 · Cited by 96
Hiraki, M., Nishimura, J., Takahashi, H., Wu, X., Takahashi, Y., Miyo, M., Nishida, N., Uemura, M., Hata, T., Takemasa, I., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.5 · Cited by 97
Corso, S., & Giordano, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0040 · Cited by 96
Shahriyari, L. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx153 · Cited by 95
The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
Reece, M. M., Saluja, H., Hollington, P., Karapetis, C. S., Vatandoust, S., Young, G. P., & Symonds, E. L. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01118 · Cited by 95
Jankú, F., Angenendt, P., Tsimberidou, A. M., Fu, S., Naing, A., Falchook, G. S., Hong, D. S., Holley, V. R., Cabrilo, G., Wheler, J. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3373 · Cited by 94
Consensus on precision medicine for metastatic cancers: a report from the MAP conference
Swanton, C., Soria, J., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S.-Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw192 · Cited by 94
Self-citationBando, H., Kagawa, Y., Kato, T., Akagi, K., Denda, T., Nishina, T., Komatsu, Y., Oki, E., Kudo, T., Kumamoto, H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0457-y · Cited by 94
Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5640 · Cited by 93
Self-citationBahcall, M., Awad, M. M., Sholl, L. M., Wilson, F. H., Xu, M., Wang, S., Palakurthi, S. S., Choi, J., Ivanova, E. V., Leonardi, G. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0876 · Cited by 93
Recent advances in circulating nucleic acids in oncology
Otandault, A., Anker, P., Dache, Z. A. A., Guillaumon, V., Meddeb, R., Pastor, B., Pisareva, E., Sánchez, C., Tanos, R., Tousch, G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz031 · Cited by 94
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis
O’Leary, B., Hrebien, S., Beaney, M., Fribbens, C. V., García-Murillas, I., Jiang, J., Li, Y., Bartlett, C. H., André, F., Loibl, S., et al. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.305805 · Cited by 93
Nano-enabled colorectal cancer therapy
Pan, Q., Xi, F., Xie, L. W., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.014 · Cited by 93
Blank, A., ROBERTS, D. E., Dawson, H., Zlobec, I., & Lugli, A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00234 · Cited by 93
Roles of Oncogenic Long Non-coding RNAs in Cancer Development
Do, H., & Kim, W. (2018) · Genomics & Informatics · doi:10.5808/gi.2018.16.4.e18 · Cited by 92
Sabra, R., Billa, N., & Roberts, C. J. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118775 · Cited by 92
van de Haar, J., Ma, X., Ooft, S., van der Helm, P. W., Hoes, L. R., Mainardi, S., Pinato, D. J., Sun, K., Salvatore, L., Tortora, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02240-8 · Cited by 92
Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Spindler, K. G., Boysen, A. K., Pallisgaard, N., Johansen, J. S., Tabernero, J. M., Mau‐Sørensen, M., Jensen, B. V., Hansen, T. F., Sefrioui, D., Andersen, R. F., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0178 · Cited by 91
Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution
Shlyakhtina, Y., Moran, K. L., & Portal, M. M. (2021) · Cancers · doi:10.3390/cancers13061380 · Cited by 91
van Grieken, N. C. T., Aoyma, T., Chambers, P. A., Bottomley, D., Ward, L. C., Inam, I. Z., Buffart, T. E., Das, K., Lim, T. W., Pang, B., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.109 · Cited by 91
Tumor heterogeneity and circulating tumor cells
Zhang, C., Guan, Y., Sun, Y., Ai, D., & Guo, Q. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.024 · Cited by 90
The microcosmos of intratumor heterogeneity: the space-time of cancer evolution
Janiszewska, M. (2019) · Oncogene · doi:10.1038/s41388-019-1127-5 · Cited by 90
Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics
Stella, G. M., Luisetti, M., Pozzi, E., & Comoglio, P. M. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70009-2 · Cited by 90
Spindler, K. G., Pallisgaard, N., Andersen, R. F., & Jakobsen, A. K. M. (2014) · International Journal of Cancer · doi:10.1002/ijc.28863 · Cited by 90
Mauri, G., Pizzutilo, E. G., Amatu, A., Bencardino, K. B., Palmeri, L., Bonazzina, E. F., Tosi, F., Stella, G. C., Burrafato, G., Scaglione, F., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.006 · Cited by 90
Self-citationCirculating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer
Arisi, M. F., Dotan, E., & Fernandez, S. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084441 · Cited by 89
Mattia, E. D., Cecchin, E., & Toffoli, G. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.003 · Cited by 89
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 88
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
Siravegna, G., & Bardelli, A. (2014) · Genome biology · doi:10.1186/s13059-014-0449-4 · Cited by 88
Self-citationLiquid biopsy for cancer: review and implications for the radiologist
Underwood, J. J., Quadri, R. S., Kalva, S. P., Shah, H., Sanjeeviah, A. R., Beg, M. S., & Sutphin, P. D. (2020) · Radiology · doi:10.1148/radiol.2019182584 · Cited by 87
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Kim, S. T., Lee, W.-S., Lanman, R. B., Mortimer, S., Zill, O. A., Kim, S. H., Jang, K. T., Kim, S.-H., Park, S. H., Park, J. O., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5465 · Cited by 87
Emerging Roles of SIRT1 in Cancer Drug Resistance
Wang, Z., & Chen, W. (2013) · Genes & Cancer · doi:10.1177/1947601912473826 · Cited by 87
Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms
Wang, J., & Bettegowda, C. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.08.007 · Cited by 87
Strategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
Self-citationPek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene · doi:10.1038/onc.2017.120 · Cited by 86
Bronte, G., Silvestris, N., Castiglia, M., Galvano, A., Passiglia, F., Sortino, G., Cicero, G., Rolfo, C. D., Peeters, M., Bazan, V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4959 · Cited by 85
Re, M. D., Tiseo, M., Bordi, P., D’Incecco, A., Camerini, A., Petrini, I., Lucchesi, M., Inno, A., Spada, D., Vasile, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6957 · Cited by 85
The challenge of intratumour heterogeneity in precision medicine
Seoane, J., & Mattos‐Arruda, L. D. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12240 · Cited by 85
Yamada, T., Iwai, T., Takahashi, G., Kan, H., Koizumi, M., Matsuda, A., Shinji, S., Yamagishi, A., Yokoyama, Y., Tatsuguchi, A., et al. (2016) · Cancer Science · doi:10.1111/cas.12959 · Cited by 85
Guernet, A. A., Mungamuri, S. K., Cartier, D., Sachidanandam, R., Jayaprakash, A. D., Adriouch, S., Vézain, M., Charbonnier, F., Rohkin, G., Coutant, S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.017 · Cited by 85
Parseghian, C. M., Sun, R., Woods, M. N., Napolitano, S., Lee, H. M., Alshenaifi, J. Y., Willis, J. A., Nunez, S., Raghav, K. P. S., Morris, V. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01423 · Cited by 84
Long non-coding RNAs and JAK/STAT signaling pathway regulation in colorectal cancer development
Ghasemian, A., Omear, H. A., Mansoori, Y., Mansouri, P., Deng, X., Darbeheshti, F., Zarenezhad, E., Kohansal, M., Pezeshki, B., Wang, Z., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1297093 · Cited by 84
The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition
Varano, G., Raffel, S., Sormani, M., Zanardi, F., Lonardi, S., Zasada, C., Perucho, L., Petrocelli, V., Haake, A., Lee, A. K., et al. (2017) · Nature · doi:10.1038/nature22353 · Cited by 84
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer
Stiegelbauer, V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i33.11727 · Cited by 83
Veluchamy, J. P., Spanholtz, J., Tordoir, M., Thijssen, V. L., Heideman, D. A. M., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157830 · Cited by 83
The clonal evolution of metastatic colorectal cancer
Dang, H. X., Krasnick, B. A., White, B. S., Grossman, J. G., Strand, M. S., Zhang, J., Cabanski, C. R., Miller, C. A., Fulton, R. S., Goedegebuure, S. P., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9691 · Cited by 83
Pettazzoni, P., Viale, A., Shah, P. K., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1854 · Cited by 83
Shitara, K., Yamanaka, T., Denda, T., Tsuji, Y., Shinozaki, K., Komatsu, Y., Kobayashi, Y., Furuse, J., Okuda, H., Asayama, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy526 · Cited by 83
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82
“To address these challenges, Mirati Therapeutics conducted high-resolution crystal structure analyses of compounds bound to mutant KRAS proteins, optimizing these compounds to develop MRTX1133, a non-covalent, selective inhibitor for KRAS G12D [60].”
InfluentialOvercoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82
Braig, F., Voigtlaender, M., Schieferdecker, A., Busch, C., Laban, S. A., Grob, T. J., Kriegs, M., Knecht, R., Bokemeyer, C., & Binder, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8943 · Cited by 82
Therapeutic and prognostic insights from the analysis of cancer mutational signatures
Brady, S. W., Gout, A. M., & Zhang, J. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.08.007 · Cited by 82
Romano, G., Chen, P.-L., Song, P., McQuade, J. L., Liang, R. J., Liu, M., Roh, W., Duose, D. Y., Carapeto, F. C. L., Li, ., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0745 · Cited by 81
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)
Jung, K., Kang, H., & Mehra, R. (2018) · Cancers of the Head & Neck · doi:10.1186/s41199-018-0030-z · Cited by 78
Liquid Biopsy for the Management of Patients with Colorectal Cancer
Yamada, T., Matsuda, A., Koizumi, M., Shinji, S., Takahashi, G., Iwai, T., Takeda, K., Ueda, K., Yokoyama, Y., Hara, K., et al. (2018) · Digestion · doi:10.1159/000494411 · Cited by 81
Osumi, H., Shinozaki, E., Takeda, Y., Wakatsuki, T., Ichimura, T., Saiura, A., Yamaguchi, K., Takahashi, S., Noda, T., & Zembutsu, H. (2018) · Cancer Medicine · doi:10.1002/cam4.1913 · Cited by 81
Measuring Clonal Evolution in Cancer with Genomics
Williams, M. J., Sottoriva, A., & Graham, T. A. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021712 · Cited by 83
RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth
Depeille, P., Henricks, L. M., van de Ven, R. A. H., Lemmens, E., Wang, C.-Y., Matli, M., Werb, Z., Haigis, K. M., Donner, D., Warren, R., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3175 · Cited by 80
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Activation of RAS family members confers resistance to ROS1 targeting drugs
Cargnelutti, M., Corso, S., Pergolizzi, M., Mévellec, L., Aisner, D. L., Dziadziuszko, R., Varella‐Garcia, M., Comoglio, P. M., Doebele, R. C., Vialard, J. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3311 · Cited by 80
Kukita, Y., Matoba, R., Uchida, J., Hamakawa, T., Doki, Y., Imamura, F., & Kato, K. (2015) · DNA Research · doi:10.1093/dnares/dsv010 · Cited by 80
Heliebi, A. E., Hille, C., Laxman, N., Svedlund, J., Haudum, C. W., Ercan, E., Kroneis, T., Chen, S., Smolle, M. A., Rossmann, C. H., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.281295 · Cited by 80
Systemic treatment for metastatic colorectal cancer in the era of precision medicine
Sandhu, J. S., Lavingia, V. K., & Fakih, M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25421 · Cited by 80
Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope?
Crigna, A. T., Samec, M., Koklesová, L., Líšková, A., Giordano, F. A., Kubatka, P., & Golubnitschaja, O. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00226-x · Cited by 80
Caputo, V., Ciardiello, F., Corte, C. M. D., Martini, G., Troiani, T., & Napolitano, S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00125 · Cited by 80
Kawakami, H., Okamoto, I., Yonesaka, K., Okamoto, K., Shibata, K., Shinkai, Y., Sakamoto, H., Kitano, M., Tamura, T., Nishio, K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2663 · Cited by 80
Holm, M., Andersson, E. I., Österlund, E., Ovissi, A., Soveri, L., Anttonen, A., Kytölä, S. I., Aittomäki, K., Osterlund, P. J., & Ristimaki, A. P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239819 · Cited by 79
Jankú, F., Huang, H. J., Claes, B., Falchook, G. S., Fu, S., Hong, D. S., Ramzanali, N. M., Nitti, G., Cabrilo, G., Tsimberidou, A. M., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0712 · Cited by 78
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taïeb, J., Jung, A., Bianchi, A. S., Peeters, M., Seligmann, J. F., Zaanan, A., Burdon, P., Montagut, C. O., & Laurent‐Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 78
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Kaseb, A. O., Sánchez, N., Sen, S., Kelley, R. K., Tan, B. R., Bocobo, A. G., Lim, K., Abdel‐Wahab, R., Uemura, M. I., Pestana, R. C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3341 · Cited by 78
Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies
Munnik, C., Xaba, M. P., Malindisa, S. T., Russell, B. L., & Sooklal, S. A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.949241 · Cited by 80
Oncoapoptotic signaling and deregulated target genes in cancers: Special reference to oral cancer
Khan, Z., & Bisen, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.04.002 · Cited by 78
Nielsen, D. L., Palshof, J. A., Larsen, F. O., Jensen, B. V., & Pfeiffer, P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.006 · Cited by 78
Xu, J.-M., Wang, Y., Wang, Y., Wang, Y., Liu, T., Ni, M., Li, M., Li, L., Ge, F.-J., Gong, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2738 · Cited by 78
Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer
Toda, K., Nishikawa, G., Iwamoto, M., Itatani, Y., Takahashi, R., Sakai, Y., & Kawada, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081632 · Cited by 77
Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77
Martínez‐Martí, A., Felip, E., Matito, J., Mereu, E., Navarro, A., Cedrés, S., Pardo, N., de Castro, A. M. M., Remón, J., Miquel, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx396 · Cited by 77
Hazar-Rethinam, M. H., Kleyman, M., Han, G. C., Liu, D., Ahronian, L. G., Shahzade, H. A., Chen, L., Parikh, A. R., Allen, J. N., Clark, J. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1227 · Cited by 77
Liquid biopsy into the clinics: Current evidence and future perspectives
Boukovala, M. A., Westphalen, C. B., & Probst, V. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100146 · Cited by 77
Drug resistance in cancer: molecular evolution and compensatory proliferation
Friedman, R. (2016) · Oncotarget · doi:10.18632/oncotarget.7459 · Cited by 77
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
Sickmier, E. A., Kurzeja, R. J. M., Michelsen, K., Vazir, M., Yang, E., & Tasker, A. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163366 · Cited by 76
Beije, N., Helmijr, J., Weerts, M. J. A., Beaufort, C. M., Wiggin, M., Marziali, A., Verhoef, C. K., Sleijfer, S., Jansen, M. P. H. M., & Martens, J. W. M. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.10.001 · Cited by 76
Clinical Trials and Progress in Metastatic Colon Cancer
Mody, K., & Bekaii‐Saab, T. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.11.008 · Cited by 76
Zhang, L., Liang, Y., Li, S., Zeng, F., Meng, Y., Chen, Z., Liu, S., Tao, Y., & Yu, F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0989-z · Cited by 76
Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery
Rosenkranz, A. A., & Slastnikova, T. A. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920090011 · Cited by 76
Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA
Hayashi, M., Chu, D. T. W., Meyer, C. F., Llosa, N. J., McCarty, G., Morris, C. D., Levin, A. S., Wolinsky, J., Albert, C. M., Steppan, D. A., et al. (2016) · Cancer · doi:10.1002/cncr.30144 · Cited by 76
Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics
Lee, H., Park, C., Na, W., Park, K. H., & Shin, S. (2020) · npj Precision Oncology · doi:10.1038/s41698-019-0107-0 · Cited by 75
Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy
Pahle, J., Menzel, L., Niesler, N., Kobelt, D., Aumann, J., Rivera, M., & Walther, W. (2017) · BMC Cancer · doi:10.1186/s12885-017-3123-x · Cited by 75
Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology
Ponti, G., Manfredini, M., & Tomasi, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.005 · Cited by 75
Helden, E. J. V., Angus, L., van Oordt, C. W. M. D. H., Heideman, D. A. M., Boon, E., van Es, S. C., Radema, S. A., van Herpen, C. M. L., de Groot, D. J. A., de Vries, E. G. E., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12550 · Cited by 75
Imaging biomarkers in oncology: Basics and application to MRI
Dregely, I., Prezzi, D., Kelly‐Morland, C., Roccia, E., Neji, R., & Goh, V. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26058 · Cited by 74
Kosmidou, V., Oikonomou, E., Vlassi, M., Avlonitis, S., Katseli, A., Tsipras, I., Mourtzoukou, D., Kontogeorgos, G., Zografos, G., & Pintzas, A. (2013) · Human Mutation · doi:10.1002/humu.22496 · Cited by 74
Adaptive stress signaling in targeted cancer therapy resistance
Pazarentzos, E., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.26 · Cited by 73
Sefrioui, D., Sarafan‐Vasseur, N., Beaussire, L., Baretti, M., Gangloff, A., Blanchard, F., Clatot, F., Sabourin, J., Sesboüé, R., Frébourg, T., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.05.023 · Cited by 73
Li, T. X., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00014-6 · Cited by 73
Imamura, T., Komatsu, S., Ichikawa, D., Kawaguchi, T., Miyamae, M., Okajima, W., Ohashi, T., Arita, T., Konishi, H., Shiozaki, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i25.5627 · Cited by 73
Liu, H., Murphy, C. J., Karreth, F. A., Emdal, K. B., White, F. M., Elemento, O., Toker, A., Wulf, G. M., & Cantley, L. C. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0679 · Cited by 73
Eng, C., Bessudo, A., Hart, L. L., Severtsev, A., Gladkov, O., Müller, L., Kopp, M. V., Vladimirov, V., Langdon, R., Kotiv, B., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30049 · Cited by 72
Metadata
- Authors
- Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., Bencardino, K., Cercek, A., Chen, C.-T., Veronese, S., Zanon, C., Sartore-Bianchi, A., Gambacorta, M., Gallicchio, M., Vakiani, E., Boscaro, V., Medico, E., Weiser, M., Siena, S., Di Nicolantonio, F., Solit, D., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Memorial Sloan Kettering Cancer Center (US)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Solit, David
- Bardelli, Alberto
- ORCID
- Venue
- Nature
- Published
- 2012-06
- Volume
- 486
- Issue
- 7404
- Pages
- 532-536
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3927413
- OpenAlex
- W2062109911
- Cited by
- 1,889
- References
- 25
- Citations by year
- 2026: 75 · 2025: 73 · 2024: 81 · 2023: 115 · 2022: 129 · 2021: 138 · 2020: 134 · 2019: 163 · 2018: 161 · 2017: 171 · 2016: 177 · 2015: 163 · 2014: 145 · 2013: 133 · 2012: 28
- FWCI
- 73.66
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- European Commission (259015)
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- National Cancer Institute (R01CA127240, P30CA008748, T32CA009207, R25CA020449)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS mutation, acquired drug resistance, anti-EGFR therapy, cetuximab resistance, colorectal cancer, EGFR, K-ras oncogene, circulating tumor DNA, tumor subclones, MEK inhibition, combination therapy, metastatic colorectal cancer, tumor heterogeneity
- MeSH terms
- Cetuximab, Panitumumab, Alleles, Antibodies, Monoclonal, Humans, Mutation, Promoter Regions, Genetic, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease Progression, ras Proteins, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
